Effective specific activities determined by scintillation proximity counting for production runs of [18F]FES and 4F-M[18F]FES

Nuclear Medicine and Biology

Volumn 34, Issue 3, 2007, Pages 325-329

  Beauregard, Jean Mathieu ^a   Croteau, Etienne ^a   Ahmed, Naseem ^a   Ouellette, René ^a   van Lier, Johan E ^a   Bénard, François ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

4 Fluoro 11 methoxy 16 18F fluoroestradiol; 18F Fluoroestradiol; Breast cancer; Estrogen receptors; Positron emission tomography; Receptor binding; Specific activity

Indexed keywords

4 FLUORO 11H METHOXY 16ALPHA FLUOROESTRADIOL F 18; BUFFER; ESTRADIOL TRITIUM; ESTROGEN RECEPTOR; FLUOROESTRADIOL F 18; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOISOTOPE DECAY; RECEPTOR BINDING; REPRODUCIBILITY; SCINTILLATION; STEREOCHEMISTRY;

ESTRADIOL; ISOTOPE LABELING; QUALITY ASSURANCE, HEALTH CARE; RADIATION DOSAGE; RADIOPHARMACEUTICALS; SCINTILLATION COUNTING;

EID: 33947314154     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.01.001     Document Type: Article

References (16)

1. Katzenellenbogen J.A. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 36 (1995) 8S-13S
2. Cummins C.H. Radiolabeled steroidal estrogens in cancer research. Steroids 58 (1993) 245-259
3. Flanagan F.L., Dehdashti F., and Siegel B.A. PET in breast cancer. Semin Nucl Med 28 (1998) 290-302
4. Jonson S.D., and Welch M.J. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 42 (1998) 8-17
5. 18F-Labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 67 (2002) 765-775
6. 18F]fluorine substitution at the 16[alpha]-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol 31 (2004) 691-698
7. Kilbourn M.R., and Zalutsky M.R. Research and clinical potential of receptor based radiopharmaceuticals. J Nucl Med 26 (1985) 655-662
8. Katzenellenbogen J.A., Heiman D.F., Carlson K.E., and Lloyd J.E. In vivo and in vitro steroids receptor assays in the design of estrogen radiopharmaceuticals. In: Eckelman W.C. (Ed). Receptor binding radiotracers (1982), CRC Press, Boca Raton (Fla) 93-126
9. Katzenellenbogen J.A., Johnson Jr. H.J., and Myers H.N. Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 12 (1973) 4085-4092
10. Senderoff S.G., McElvany K.D., Carlson K.E., Heiman D.F., Katzenellenbogen J.A., and Welch M.J. Methodology for the synthesis and specific activity determination of 16-alpha-[77Br]-bromoestradiol-17-beta and 16-alpha-[77Br]-11-beta-methoxyestradiol-17-beta, two estrogen receptor-binding radiopharmaceuticals. Int J Appl Radiat Isot 33 (1982) 545-551
11. Kiesewetter D.O., Kilbourn M.R., Landvatter S.W., Heiman D.F., Katzenellenbogen J.A., and Welch M.J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 25 (1984) 1212-1221
12. Allan G.F., Hutchins A., and Clancy J. An ultrahigh-throughput screening assay for estrogen receptor ligands. Anal Biochem 275 (1999) 243-247
13. Levesque C., Merand Y., Dufour J.M., Labrie C., and Labrie F. Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 34 (1991) 1624-1630
14. Fevig T.L., Mao M.K., and Katzenellenbogen J.A. Estrogen receptor binding tolerance of 16 alpha-substituted estradiol derivatives. Steroids 51 (1988) 471-497
15. 18F]fluoro-17-beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32 (1991) 1526-1531
16. Heiman D.F., Senderoff S.G., Katzenellenbogen J.A., and Neeley R.J. Estrogen receptor based imaging agents: 1. Synthesis and receptor binding affinity of some aromatic and D-ring halogenated estrogens. J Med Chem 23 (1980) 994-1002